IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Martin A. CHEEVER et al.

Serial No.: 09/854,356 Art Unit: 1642

Filing Date: May 9, 2001 Examiner: Misook Yu

For: HER-2/NEU FUSION PROTEINS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

the	LAMIIII	and officially made of record in accordance with the provisions of 37 CTR 1.77		
	[] Co	ppies of the references are enclosed ppies of the references were submitted in parent application Serial No		
		7 CFR 1.98(d)) copy of the International Search Report which issued on International Application No is submitted herewith. All of the publications cited in the International Search Report listed on the attached form PTO-1449 and Applicants understand that copies have been pplied to the U.S. Patent Office by the International Bureau.		
Α.	[X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national st of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).			
	OR			
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).		
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.		

At	ty. Dock	set No. CRX113US1
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.
	In acco	ordance with the requirements of 37 CFR 1.97(d):
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
		charge any required fees to Deposit Account No.07-1392. icate copy of this paper is attached.
		Respectfully Submitted,
		/Virginia G. Campen/ Virginia G. Campen Attorney of Record

Registration No. 37,092

Date: 2 Nov. 2006
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1012 Facsimile: (919) 483-7988

FORM PTO INFORMA		DISCLOSURE S	TATEMENT	FILING I APPLICA GROUP EXAMIN	SERIAL NO. FILING DATE APPLICANT GROUP EXAMINER ATTORNEY DOCKET NO.		09/854,356 May 9, 2001 Cheever 1642 Misook Yu . CRX113US1	
			I S II	PATENT DOCUMENT		. CRAIL	0031	
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
	1.	5,801,005	9/1/1998	Cheever et al.				
	-	1				+	+	
		+				+	+	
							†	
						-	1	
			+			+		
			FOREIG	I ON PATENT DOCUME	NTS	1		
		Document	Publication	T TATE OF COME	TATELY DOCUMENTS		Translation	
		Number	Date	Country	Class	Subclass	Yes No	
							1	
	1	 				+	 	
		+				+		
			11 11 11					
	2.			ing Author, Title, Journ				
	ndocrine-Relat	ed Cancer 9:33						
44 (2002). 3. CHAMBERLAIN et al., Innovation and strategies for the development of ant							ac Evnart	
	J.	acveropment or ant	icancei vacciii	co, Expert				
Opinion on Pharmacotherapy 1(4):603-614 (2000). 4. DISIS and CHEEVER, HER-2/neu Protein: A Target for Antigen-Specific In Cancer, Advances in Cancer Research 71:343-371 (1997).							of Human	
	5.	EZZELL, Cance	Come?, Journal of N	VIH Research	7:46-49 (1995).			
		+						
		1						
		†						
				·				
					I			
EXAMINEI	₹				DATE	E CONSIDERI	ED	